September 30, 2022

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

September 27, 2022

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

September 05, 2022

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

August 11, 2022

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

August 04, 2022

Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

August 04, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

July 29, 2022

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

July 15, 2022

Synthetic Biologics Announces Reverse Stock Split

May 16, 2022

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

May 10, 2022

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

May 09, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

May 05, 2022

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

May 04, 2022

Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

March 28, 2022

Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors

March 23, 2022

Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation

March 22, 2022

Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

March 16, 2022

Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

March 11, 2022

Synthetic Biologics Completes Acquisition of VCN Biosciences

March 10, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results

February 09, 2022

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

February 08, 2022

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

January 26, 2022

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

December 14, 2021

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

November 03, 2021

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

October 26, 2021

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

October 21, 2021

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase

October 06, 2021

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

September 21, 2021

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

August 05, 2021

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

August 03, 2021

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital

July 28, 2021

Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021

June 29, 2021

Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

May 26, 2021

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

May 05, 2021

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results

April 28, 2021

Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021

April 14, 2021

Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

April 01, 2021

Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase

March 04, 2021

Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results

February 25, 2021

Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021

December 22, 2020

Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

November 24, 2020

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

November 16, 2020

Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options

November 12, 2020

Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors

November 10, 2020

Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results

November 03, 2020

Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020

October 02, 2020

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients

August 06, 2020

Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results

July 30, 2020

Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)

July 29, 2020

Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020

June 30, 2020

Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase